ChemicalBook > CAS DataBase List > Camrelizumab

Camrelizumab

Product Name
Camrelizumab
CAS No.
1798286-48-2
Chemical Name
Camrelizumab
Synonyms
SHR-1210;Camrelizumab;Camrelizumab (anti-PD-1);Research Grade Camrelizumab;Research Grade Camrelizumab(DHH02211)
CBNumber
CB28081005
Formula Weight
0
MOL File
Mol file
More
Less

Camrelizumab Property

storage temp. 
4°C, Do not freeze, Protect from light.
form 
Solid
color 
White to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Camrelizumab Chemical Properties,Usage,Production

Uses

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab?binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as?anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al[1][2].

in vivo

Camrelizumab (3 mg/kg) combines with apatinib (200 and 100 mg/kg) inhibits the tumor inhibition rates reached 63.1% and 87.3%, respectively in human PD-1 transgenic mice[1].

References

[1] Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191. DOI:10.1136/jitc-2020-002191
[2] Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther DOI:10.2147/DDDT.S243787
[3] Caicun Zho, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med.?2021 Mar;9(3):305-314. DOI:10.1016/S2213-2600(20)30365-9

Camrelizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Camrelizumab Suppliers

BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Country
United States
ProdList
12952
Advantage
65
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9803
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Kaifeng Mingren Pharmaceutical Co.,LTD
Tel
0371-65741762
Fax
QQ:2860768577
Email
sales@hasunny.com
Country
China
ProdList
2380
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Shanghai Tachizaki Biomedical Research Center
Tel
18014399201
Email
sales@chemlab-tachizaki.com
Country
China
ProdList
2742
Advantage
58
Shanghai Yiyan Biotechnology Co. , Ltd.
Tel
021-69985186 13611928337
Email
3427709316@qq.com
Country
China
ProdList
7982
Advantage
58

1798286-48-2, CamrelizumabRelated Search:


  • Camrelizumab
  • Camrelizumab (anti-PD-1)
  • Research Grade Camrelizumab(DHH02211)
  • SHR-1210
  • Research Grade Camrelizumab
  • 1798286-48-2